Ashfield announces leadership changes in the U.S. and Japan

Greg Flynn will oversee U.S. operations of Commercial, Clinical, Medical Information, Pharmacovigilance and Market Access. Greg is transitioning to this role from his prior position as Regional President in Japan and Representative Director of CMIC Ashfield, a joint initiative between CMIC Holdings Co., Ltd and UDG Healthcare plc. Under Greg’s leadership, Ashfield became an industry leading partner with over 650 staff across 44 clients in five years.

Mick O’Leary will take over the role as Regional President in Japan, leading the CMIC Ashfield joint venture. Mick was previously the Managing Director for Ashfield Ireland, and has over 20 years’ experience in the pharmaceutical sales industry. Under Mick’s leadership, Ashfield has been established as the Number 1 CSO in Ireland with over 60% market share.

Commenting on his appointment, Greg Flynn said: “Through the talent of our people and Ashfield’s commitment to helping improve lives, I have seen the power of what we do in this organisation. The U.S. business has experienced phenomenal growth in the last two years and this new role is an exciting opportunity to continue that growth. I am excited about the future of Ashfield in the U.S. and being part of the next phase in this company’s journey.”
Mick O’Leary commented, “I am delighted to accept the role of Regional President in Japan and support the group’s overall strategy of expansion in growth markets. CMIC Ashfield is a winning p...

Source: Ashfield Healthcare News - June 13, 2017 Category: Pharmaceuticals Authors: Jane Neale Tags: Ashfield Source Type: news